<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="161263">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01660295</url>
  </required_header>
  <id_info>
    <org_study_id>CMEX839BDE07</org_study_id>
    <secondary_id>2011-001930-40</secondary_id>
    <nct_id>NCT01660295</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Certoparin in Subjects With Renal Insufficiency and Healthy Subjects</brief_title>
  <official_title>An Open-label, Single Center, Parallel-group Study to Compare the Single- and Repeated-dose Pharmacokinetics of Stepwise Increasing Doses of Subcutaneous Certoparin (3000 IU o.d., 3000 IU b.i.d., 8000 IU o.d., and 8000 IU b.i.d.) in Subjects With Severe Renal Insufficiency and Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>Hungary:  GYEMSZI - Országos Gyógyszerészeti Intézet</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the pharmacokinetics in subjects with severe renal insufficiency and
      healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Plasma aXa-Profile: C0</measure>
    <time_frame>5 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Estimate of the effects of renal insufficiency on the systemic exposure to aXa for once daily (τ = 24 h) repeated doses of 3,000 IU aXa as characterized by  pre-dose trough (C0,ss) aXa comparing REN-patients with matched CON-subjects studied in parallel.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose regimen, systemic total exposure to aXa (AUC0-τ,ss)</measure>
    <time_frame>5 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Dosage regimen (3,000 o.d., 3,000 b.i.d., 8,000 o.d., 8,000 IU aXa in the morning plus 3,000 IU aXa in the evening, or 8,000 b.i.d. IU aXa) that yields a systemic total exposure to aXa (AUC0-τ,ss) in REN-patients similar to that achieved with 8,000 b.i.d. IU aXa in CON-subjects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma aXa-Profile: Cmax</measure>
    <time_frame>5 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Estimate of the effects of renal insufficiency on the systemic exposure to aXa for once daily (τ = 24 h) repeated doses of 3,000 IU aXa as characterized by maximum (Cmax,ss), aXa comparing REN-patients with matched CON-subjects studied in parallel.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma aXa-Profile: AUC</measure>
    <time_frame>5 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Estimate of the effects of renal insufficiency on the systemic exposure to aXa for once daily (τ = 24 h) repeated doses of 3,000 IU aXa as characterized by total (AUC0-τ,ss) aXa comparing REN-patients with matched CON-subjects studied in parallel.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Renal Insufficiency</condition>
  <arm_group>
    <arm_group_label>Certoparin control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive Certoparin 3,000 IU during period 1. Participants will receive 8,000 IU during period 2, if qualified as per medical criteria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Certoparin Renal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive dose escalation upon medical criteria qualification at each period:
Certoparin 3,000 IU once a day during period 1. Certoparin 3,000 IU twice a day during period 2. Certoparin 8,000 IU once a day during period 3. Certoparin 8,000 IU in the morning and 3,000 IU in the evening during period 4 OR Certoparin 8,000 IU twice a day during period 4.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Certoparin 3,000 IU Once Daily</intervention_name>
    <description>Certoparin 3,000 IU subcutaneous injection once daily</description>
    <arm_group_label>Certoparin control</arm_group_label>
    <arm_group_label>Certoparin Renal</arm_group_label>
    <other_name>Mono-Embolex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Certoparin 3,000 IU Twice a Day</intervention_name>
    <description>Certoparin 3,000 IU subcutaneous injection twice a day</description>
    <arm_group_label>Certoparin Renal</arm_group_label>
    <other_name>Mono-Embolex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Certoparin 8,000 IU Once Daily</intervention_name>
    <description>Certoparin 8,000 IU subcutaneous injection once daily</description>
    <arm_group_label>Certoparin Renal</arm_group_label>
    <other_name>Mono-Embolex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Certoparin 8,000 IU Twice a Day</intervention_name>
    <description>Certoparin 8,000 IU subcutaneous injection twice a day</description>
    <arm_group_label>Certoparin control</arm_group_label>
    <arm_group_label>Certoparin Renal</arm_group_label>
    <other_name>Mono-Embolex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Healthy subjects OR

          -  Subjects with severe renal insufficiency

        Exclusion criteria:

          -  Hypersensitivity to study medication

          -  Genetic abnormality or disease of clotting system

          -  Prior major surgery or bleeding

          -  Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>DRC Drug Research Center Ltd., H-8230 Balatonfüred</name>
      <address>
        <city>H-8230 Balatonfüred</city>
        <state>Ady E. u.</state>
        <zip>12</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <lastchanged_date>August 5, 2012</lastchanged_date>
  <firstreceived_date>December 20, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Severe renal insufficiency certoparin</keyword>
  <keyword>Severe renal insufficiency</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Certoparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
